Dr. Michael Salgaller leads the Technology Analysis and Marketing Unit (TAMU) within the National Institute’s of Health (NIH’s) NCI Technology Transfer Center, where he leverages over 20 years of business, scientific, and investment experience in various life science sectors to support technology development and commercialization. The TAMU serves in a business development role to foster licensing and collaborative activity between buy-side stakeholders and the NCI (as well as National Institutes of Heath in general). It also provides education and assistance to tech transfer staff and investigators seeking to make a more compelling business case to potential licensees and collaborators. Previously, Dr. Salgaller was a Vice President at The Conafay Group, a healthcare-focused government affairs firm, where he led alliance development activities centered on civilian health. He served as President of Biologics Consulting Group, a boutique firm providing professional services focused on regulatory affairs. Salgaller spent several years on the investment team of an early-stage venture capital firm dedicated to the life sciences. He began his buy-side career as Vice President of R&D for Northwest Biotherapeutics, where he led the development of cancer cell therapies that achieved clinical benefit and resulting in an IPO. He began his career as a Senior Scientist with Dr. Steve Rosenberg at the NCI. He has written over 80 scientific/business articles and book chapters. He sits on the Editorial Board of Med Nous, a UK-based journal on the buiness of science. He is the author of "Biotechnology Entrepreneurship,"and teaches an entrepreneurship class at the NIH's graduate school - the Foundation for Advanced Education in the Sciences. Dr. Salgaller received his Ph.D. in Pathology from The Ohio State University.